(NASDAQ: DFTX) Definium Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.57%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.48%.
Definium Therapeutics's earnings in 2026 is -$353,785,000.On average, 20 Wall Street analysts forecast DFTX's earnings for 2026 to be -$432,097,238, with the lowest DFTX earnings forecast at -$472,729,803, and the highest DFTX earnings forecast at -$413,379,922. On average, 19 Wall Street analysts forecast DFTX's earnings for 2027 to be -$290,662,586, with the lowest DFTX earnings forecast at -$547,787,182, and the highest DFTX earnings forecast at -$119,922,503.
In 2028, DFTX is forecast to generate -$111,081,158 in earnings, with the lowest earnings forecast at -$283,111,164 and the highest earnings forecast at $650,403,221.